298 related articles for article (PubMed ID: 26871298)
1. Fluorescence-Based Transport Assays Revisited in a Human Renal Proximal Tubule Cell Line.
Caetano-Pinto P; Janssen MJ; Gijzen L; Verscheijden L; Wilmer MJ; Masereeuw R
Mol Pharm; 2016 Mar; 13(3):933-44. PubMed ID: 26871298
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters.
Caetano-Pinto P; Jamalpoor A; Ham J; Goumenou A; Mommersteeg M; Pijnenburg D; Ruijtenbeek R; Sanchez-Romero N; van Zelst B; Heil SG; Jansen J; Wilmer MJ; van Herpen CML; Masereeuw R
Mol Pharm; 2017 Jun; 14(6):2147-2157. PubMed ID: 28493713
[TBL] [Abstract][Full Text] [Related]
3. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z
Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901
[TBL] [Abstract][Full Text] [Related]
4. Proximal tubular efflux transporters involved in renal excretion of p-cresyl sulfate and p-cresyl glucuronide: Implications for chronic kidney disease pathophysiology.
Mutsaers HA; Caetano-Pinto P; Seegers AE; Dankers AC; van den Broek PH; Wetzels JF; van den Brand JA; van den Heuvel LP; Hoenderop JG; Wilmer MJ; Masereeuw R
Toxicol In Vitro; 2015 Oct; 29(7):1868-77. PubMed ID: 26216510
[TBL] [Abstract][Full Text] [Related]
5. Screening of Drug-Transporter Interactions in a 3D Microfluidic Renal Proximal Tubule on a Chip.
Vriend J; Nieskens TTG; Vormann MK; van den Berge BT; van den Heuvel A; Russel FGM; Suter-Dick L; Lanz HL; Vulto P; Masereeuw R; Wilmer MJ
AAPS J; 2018 Jul; 20(5):87. PubMed ID: 30051196
[TBL] [Abstract][Full Text] [Related]
6. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
[TBL] [Abstract][Full Text] [Related]
7. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
[TBL] [Abstract][Full Text] [Related]
8. A morphological and functional comparison of proximal tubule cell lines established from human urine and kidney tissue.
Jansen J; Schophuizen CMS; Wilmer MJ; Lahham SHM; Mutsaers HAM; Wetzels JFM; Bank RA; van den Heuvel LP; Hoenderop JG; Masereeuw R
Exp Cell Res; 2014 Apr; 323(1):87-99. PubMed ID: 24560744
[TBL] [Abstract][Full Text] [Related]
9. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
Chen X; Unadkat JD; Mao Q
Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
[TBL] [Abstract][Full Text] [Related]
10. Chemical inhibition and stable knock-down of efflux transporters leads to reduced glucuronidation of wushanicaritin in UGT1A1-overexpressing HeLa cells: the role of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) in the excretion of glucuronides.
Qin Z; Li S; Yao Z; Hong X; Wu B; Krausz KW; Gonzalez FJ; Gao H; Yao X
Food Funct; 2018 Mar; 9(3):1410-1423. PubMed ID: 29318243
[TBL] [Abstract][Full Text] [Related]
11. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
[TBL] [Abstract][Full Text] [Related]
12. Correlation between Membrane Protein Expression Levels and Transcellular Transport Activity for Breast Cancer Resistance Protein.
Liu H; Huang L; Li Y; Fu T; Sun X; Zhang YY; Gao R; Chen Q; Zhang W; Sahi J; Summerfield S; Dong K
Drug Metab Dispos; 2017 May; 45(5):449-456. PubMed ID: 28209803
[TBL] [Abstract][Full Text] [Related]
13. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
Xiao L; Yi T; Chen M; Lam CW; Zhou H
Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Amino Acid/Drug Transporters for Renal Transport of [
Ono M; Baden A; Okudaira H; Kobayashi M; Kawai K; Oka S; Yoshimura H
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27754421
[TBL] [Abstract][Full Text] [Related]
15. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.
Hoque MT; Kis O; De Rosa MF; Bendayan R
Antimicrob Agents Chemother; 2015 May; 59(5):2572-82. PubMed ID: 25691630
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines.
Mukkavilli R; Jadhav G; Vangala S
Curr Pharm Biotechnol; 2017; 18(14):1151-1158. PubMed ID: 29521222
[TBL] [Abstract][Full Text] [Related]
17. Ochratoxin A transport by the human breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), and organic anion-transporting polypeptides 1A2, 1B1 and 2B1.
Qi X; Wagenaar E; Xu W; Huang K; Schinkel AH
Toxicol Appl Pharmacol; 2017 Aug; 329():18-25. PubMed ID: 28532671
[TBL] [Abstract][Full Text] [Related]
18. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease K; Sane R; Podila L; Taub ME
J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
[TBL] [Abstract][Full Text] [Related]
19. Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-
Bicker J; Fortuna A; Alves G; Soares-da-Silva P; Falcão A
Drug Metab Dispos; 2017 Dec; 45(12):1282-1291. PubMed ID: 28916530
[TBL] [Abstract][Full Text] [Related]
20. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
D'Cunha R; Bae S; Murry DJ; An G
Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
